Evidence map›Paper›PMID 37157047›Full record

ArticleBulletin of experimental biology and medicine2023

Efficacy of the Technologically Processed Antibodies to the Brain-Specific S100 Protein in a Rat Model of Hemorrhagic Stroke.

E V Kardash, I A Ertuzun, I V Alekseeva, S A Tarasov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Effect of Frequency of Prospekta Administration: Anxiolytic Effect in Wistar Rats.Dose-response : a publication of International Hormesis Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

E V KardashResearch Institute of General Pathology and Pathophysiology, Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Moscow, Russia. kardashelv@yandex.ru.
I A ErtuzunLLC "MATERIA MEDICA HOLDING", Moscow, Russia.
I V AlekseevaLaboratory of Systemic Mechanisms of Emotional Stress, P. K. Anokhin Research Institute of Normal Physiology, Moscow, Russia.
S A TarasovResearch Institute of General Pathology and Pathophysiology, Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the ability of technologically processed antibodies to the brain-specific S100 protein (drug Prospekta) to reduce the brain lesion area, neurological disorders, and mortality in a rat model of hemorrhagic stroke. Technologically processed antibodies to S100 exerted a positive effect on all these parameters (brain lesion area, survival rate, neurological status according to the Menzies scale, and proportion of contralateral turns). This allows us to recommend further research into the spectrum of pharmacological activity and the mechanism of action of technologically processed antibodies to S100 in order to expand the indications for their use after the necessary clinical trials.

Indexed as

Brain IschemiaHemorrhagic StrokeStrokeAnimalsBrainRatsS100 ProteinsS100 Proteinshemorrhagic strokenimodipineProspektarats

Identifiers

PMID37157047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.